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• The average effect of CST on symptoms of anxiety and depression in cancer patients are statistically significant but small• Younger patients and patients who received chemotherapy benefit more from CST• CST effects are larger when delivered face-to-face, led by a psychologist and targeted to patients with psychological distress
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A B S T R A C T
Purpose: This study evaluated the effects of coping skills training (CST) on symptoms of depression and anxiety
in cancer patients, and investigated moderators of the effects.
Methods: Overall effects and intervention-related moderators were studied in meta-analyses of pooled aggregate
data from 38 randomized controlled trials (RCTs). Patient-related moderators were examined using linear mixed-
effect models with interaction tests on pooled individual patient data (n = 1953) from 15 of the RCTs.
Results: CST had a statistically significant but small effect on depression (g = −0.31,95% confidence interval
(CI) = −0.40;-0.22) and anxiety (g = −0.32,95%CI = -0.41;-0.24) symptoms. Effects on depression symptoms
were significantly larger for interventions delivered face-to-face (p = .003), led by a psychologist (p = .02) and
targeted to patients with psychological distress (p = .002). Significantly larger reductions in anxiety symptoms
were found in younger patients (pinteraction < 0.025), with the largest reductions in patients< 50 years
(β =−0.31,95%CI = -0.44;-0.18) and no significant effects in patients ≥70 years. Effects of CST on depression
(β =−0.16,95%CI = -0.25;-0.07) and anxiety (β =−0.24,95%CI = -0.33;-0.14) symptoms were significant in
patients who received chemotherapy but not in patients who did not (pinteraction < 0.05).
Conclusions: CST significantly reduced symptoms of depression and anxiety in cancer patients, and particularly
when delivered face-to-face, provided by a psychologist, targeted to patients with psychological distress, and
given to patients who were younger and received chemotherapy.
1. Introduction
A substantial proportion of patients with cancer experience symp-
toms of depression and anxiety (these symptoms will be referred to as
depression and anxiety throughout the manuscript for clarity). Previous
studies found that 7–31% of patients suffer from depression and 8–19%
of patients experience anxiety, with proportions varying by the type of
cancer and assessment method (Krebber et al., 2014; Mitchell et al.,
2011; Zhu et al., 2017). Evidence suggests that, next to fatigue
(Barsevick et al., 2013) and pain (van den Beuken-van Everdingen,
Hochstenback, Joosten, Tjan-Heijnen, & Janssen, 2016), depression and
anxiety are among the most common symptoms that affect cancer pa-
tients' health-related quality of life (Cleeland et al., 2000; Dauchy,
Dolbeault, & Reich, 2013; Hutter et al., 2013; Jacobsen & Jim, 2008;
Nikbakhsh, Moudi, Abbasian, & Khafri, 2014; Pirl, 2004) and treatment
adherence (Arrieta et al., 2013; Barber et al., 2015). It is therefore
important to adequately address depression and anxiety in clinical
cancer care.
Various psychosocial interventions are available to manage de-
pression and anxiety, which can be subdivided into psycho-education,
supportive interventions with a focus on acknowledgement of problems
and expression of emotions, coping skills training (CST), (psycho-dy-
namic) psychotherapy and spiritual or existential therapy (Cunningham
A.J. 1995). Although each of these types of interventions can be used to
treat or ameliorate depression and anxiety in cancer patients, the focus
here will be on the evidence on the efficacy of CST, as this is the most
prevalent form of therapy (Kalter et al., 2018). CST, which encompasses
interventions like cognitive behavioural therapy (CBT) or problem
solving therapy, aims to enhance the patient's ability to cope with the
sequela of cancer and its treatment. In these interventions, patients
learn new cognitive-behavioural skills such as relaxation, mental ima-
gery, thought and affect management, and activity planning (Jacobsen
& Jim, 2008; Kalter et al., 2018). Results from previous meta-analyses
have shown that CST reduces depression (medium effect size of
0.34–0.38) and anxiety (medium effect size of 0.31–0.42) in patients
with cancer (Ballesio et al., 2017; Matthews, Grunfeld, & Turner, 2016;
Sheard & Maguire, 1999). However, there is a substantial heterogeneity
in effects across the different studies that may be explained by specific
patient- and intervention-related characteristics. Previous meta-ana-
lyses and randomized controlled trials (RCTs) reported larger benefits
of CST in men versus women, married versus single patients, patients
with breast cancer versus other types of cancer, patients with metastatic
versus local or loco-regional disease, patients who received che-
motherapy versus other types of treatment, interventions led by a
mental health professional versus nurses or other health care profes-
sionals, and in studies that specifically selected patients with higher
distress levels (Andersson & Cuijpers, 2009; Faller et al., 2013; Spek
et al., 2007; van der Meulen et al., 2015; Willems, Mesters, Lechner,
Kanera, & Bolman, 2017; Williams & Dale, 2006). Information on these
moderators of intervention effects is essential to better target specific
patient groups to maximize benefits of CST.
Meta-analyses in which aggregate (summary) data (AD) from a large
number of studies are pooled, allow investigations of differences in
effects across characteristics of the intervention (Lyman & Kuderer,
2005). However, AD meta-analyses do not allow testing interactions
between the intervention and potential moderator variables at the in-
dividual patient level. Rather, AD meta-analyses use measures of cen-
tral tendency (e.g., means such as with age, or proportions such as with
sex) (Riley, Lambert, & Abo-Zaid, 2010). As a consequence, moderator
effects of patient characteristics evaluated in AD meta-analyses may be
confounded by other trial characteristics, also referred to as ecological
bias (Berlin, Santanna, Schmid, Szczech, & Feldman, 2002; Riley et al.,
2010), and should therefore be interpreted with caution.
Ecological bias can be reduced by using individual patient data
(IPD) in a meta-analysis (Berlin et al., 2002; Stewart & Tierney, 2002;
Tierney et al., 2015). However, the collection of IPD is labour intensive
and time consuming and depends on the ability and willingness of in-
vestigators of eligible studies to share their data. This makes it difficult
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to include all available RCTs, which may introduce retrieval bias in
estimating the overall intervention effects (Riley et al., 2010).
In previous analyses on IPD collected in the Predicting OptimaL
Cancer RehabIlitation and Supportive care (POLARIS) study (Buffart
et al., 2013), we found small but statistically significant effects of
psychosocial interventions (including CST) on quality of life (β = 0.12,
95% confidence interval (CI) = 0.07; 0.17), emotional function
(β = 0.12, 95%CI = 0.07; 0.18) and social function (β = 0.10,
95%CI = 0.05; 0.15) (Kalter et al., 2018). Additionally, moderator
effects on one or more of these outcomes were found for age, marital
status, treatment with chemotherapy, baseline emotional function, type
of psychosocial intervention, and interventions targeting patients with
distress (Kalter et al., 2018).
In the present paper, we combine AD and IPD meta-analyses to
reduce retrieval and ecological bias, in the investigations of the effects
of CST on depression and anxiety in patients with cancer, and to
identify patient-related moderators (i.e., demographic, clinical, and
psychosocial characteristics) and intervention-related moderators of
those effects.
2. Methods
The conduct and reporting of the AD and IPD meta-analyses are
based on the Preferred reporting Items for Systematic Review and Meta-
Analyses (PRISMA) (Moher, Liberati, Tetzlaff, & Altman, 2009) and
PRISMA-IPD statement (Stewart & Tierney, 2002). The IPD were col-
lected as part of the POLARIS study. The study protocol was registered
in PROSPERO International prospective register of systematic reviews,
in February 2013 (CRD42013003805) (Buffart et al., 2013).
2.1. Identification and inclusion of studies
A literature search was conducted in April 2019 to identify studies
that could be used to examine the overall effect of CST on depression
and anxiety, and the potential moderator effects of intervention-level
characteristics via AD meta-analyses. In contrast to the original broader
literature search for POLARIS conducted in 2012 (Kalter et al., 2018),
the current literature search specifically focussed on CST and on de-
pression and anxiety as outcomes. Relevant published studies were
identified via systematic searches in five electronic databases (PubMed,
EMBASE, PsycINFO, CINAHL and CENTRAL), and reference checking of
systematic reviews and meta-analyses. Search terms included depres-
sion, anxiety, cancer, and psychosocial interventions. The full search
terms can be found in Appendix 1. Articles were included when the
study 1) was a RCT; 2) included a usual care, wait-list or attention
control group; 3) included adult patients with cancer (excluding sur-
vivors of childhood cancer); 4) measured depression and/or anxiety as
one of the outcomes using a validated multi-item questionnaire; and 5)
evaluated the effects of coping skills training, as defined by Cun-
ningham (Cunningham A.J. 1995), the goal being to help patients ac-
quire new coping skills. Studies focussing on psychoeducation, support,
psychodynamic psychotherapy, and spiritual or existential therapy
were excluded from the present analyses (Cunningham A.J. 1995;
Kalter et al., 2018).
To investigate demographic, clinical and personal (patient-level)
moderators of the effect of CST, we used IPD from the POLARIS study of
which detailed descriptions of the design and procedures have been
published previously (Buffart et al., 2013; Buffart et al., 2017; Kalter
et al., 2018; Kalter, Sweegers, Verdonck-de Leeuw, Brug, & Buffart,
2019). Briefly, IPD from 22 of 61 eligible RCTs focussing on psycho-
social interventions were included in the POLARIS database (Kalter
et al., 2018), of which 14 RCTs evaluated the effects of CST on
Fig. 1. Flowchart of inclusion randomized controlled trials (RCTs) in the POLARIS study and additionally identified RCTs in the more recent literature search.
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depression and anxiety (Armes, Chalder, Addington-Hall, Richardson, &
Hotopf, 2007; Arving et al., 2007; Braamse et al., 2016; Duijts,
Oldenburg, van Beurden, & Aaronson, 2012; Ferguson et al., 2012;
Gellaitry, Peters, Bloomfield, & Horne, 2010; Gielissen, Verhagen,
Witjes, & Bleijenberg, 2006; Goedendorp et al., 2010; Graves, Carter,
Anderson, & Winett, 2003; Heiney et al., 2003; Johansson et al., 2008;
Mann et al., 2012; Savard, Simard, Ivers, & Morin, 2005; van den Berg,
Gielissen, Custers, van der Graaf, & Ottevanger, 2015), and one addi-
tional RCT assessed the effects on depression only (Northouse et al.,
2013). Detailed information on the selection of studies can be found in
the flowchart (Fig. 1). Detailed information on reasons for not sharing
IPD is presented in our previous publication (Kalter et al., 2018).
2.2. Outcome variables
Depression and anxiety were assessed with validated, multi-item
patient-reported outcome measures (PROMs). We used baseline or pre-
intervention and the first post-intervention assessments to evaluate the
short-term intervention effects of CST on depression and anxiety. As
some studies used multiple questionnaires to assess depression and/or
anxiety, we selected the most-frequently used symptom-specific ques-
tionnaires over generic questionnaires or other symptom-specific
questionnaires for analyses. The Center for Epidemiologic Studies
Depression Scale (CES-D) was chosen over the Profile of Mood States
(POMS) depression subscale in one study (Ferguson et al., 2012), and in
three studies the depression subscale of the Hospital Anxiety and De-
pression Scale (HADS-D) was used instead of the Patient Health Ques-
tionnaire (Braamse et al., 2016), the Symptom Checklist (van den Berg
et al., 2015) and the Beck Depression Inventory (Savard et al., 2005).
For anxiety, the State-Trait Anxiety Inventory (STAI) was chosen over
the Symptom Checklist (Goedendorp et al., 2010) and the POMS an-
xiety subscale (Ferguson et al., 2012) in two studies and the HADS-A
over the Symptom Checklist (van den Berg et al., 2015). In one study
(Braamse et al., 2016), both HADS-A and STAI were included, and the
data from the HADS-A was selected as this was the most frequently used
PROM.
2.3. Possible moderators
Potential intervention-related moderators (to be used in the AD
meta-analyses) were identified from previously conducted meta-ana-
lyses (Andersson & Cuijpers, 2009; Faller et al., 2013; Kalter et al.,
2018; Schneider et al., 2010; Spek et al., 2007). They included timing
and method of intervention delivery, intervention strategy, intervention
duration, intervention focus, health-care professional leading the in-
tervention and whether the intervention targeted patients with elevated
levels of depression or anxiety. The timing of intervention delivery was
categorized as during treatment or after cancer treatment according to
the Physical Activity and Cancer Control framework (Courneya &
Friedenreich, 2007). The method of delivery was dichotomised into
face-to-face intervention or other (telephone/web−/video-based). As
cognitive behavioural therapy was the most frequently used CST, we
dichotomised intervention strategy into cognitive behavioural therapy
versus other (e.g., problem solving therapy, stress management
training, expressive writing). Intervention duration was dichotomised
into ≤12 weeks versus> 12 weeks. Intervention focus was dichot-
omised into psychological distress (anxiety/depression) versus other
outcomes (e.g., fatigue, insomnia, quality of life). The health care
professional leading the intervention was categorized as psychologist,
nurse, or other. Further, studies were dichotomised into those that
specifically targeted patients with high levels of depression and/or
anxiety before the start of the intervention and those that did not.
Potential demographic, clinical and personal moderators that we
studied in the IPD meta-analyses were identified from previous pub-
lications on the moderator effects of CST or other psychosocial inter-
ventions (Badger et al., 2013; Faller et al., 2013; Guo et al., 2013;
Heron-Speirs, Baken, & Harvey, 2012; Heron-Speirs, Harvey, & Baken,
2013). Potential demographic moderators included baseline age, sex,
marital status, education level, and baseline values of depression or
anxiety, and were categorized in line with our previous publications
(Buffart et al., 2017; Kalter et al., 2018). We dichotomised marital
status into single versus married or living with partner, and education
level into low-medium (elementary, primary, or secondary school,
lower or secondary vocational education) or high (higher vocational,
college, or university education). Baseline values for depression and
anxiety were assessed as moderators by using the pooled z-score. Po-
tential clinical moderators included type of cancer, the presence of
distant metastases at baseline, and type of cancer treatment. Type of
cancer was categorized into breast, male genitourinary, gastro-
intestinal, hematological, gynecological, respiratory tract, and other
types. The presence of distant metastasis and type of treatment (i.e.
surgery, chemotherapy, radiotherapy, SCT and hormone therapy) were
dichotomized. As hormone therapy for breast cancer may continue for
several years after treatment, women on hormone therapy only (who
completed other primary cancer treatments) were considered as being
after treatment.(Kalter et al., 2018) Men receiving androgen depriva-
tion therapy for prostate cancer were considered as being during
treatment.(Kalter et al., 2018).
2.4. Quality assessment
Two independent researchers rated the quality of the included stu-
dies from published papers using the Cochrane ‘risk of bias’ assessment
tool (J. P. Higgins et al., 2011). The quality rating of the studies with
IPD has been described previously (Kalter et al., 2018). The quality was
graded as high (+), low (−) or unclear (?) on the following aspects:
random sequence generation (high quality if a random assignment was
used), allocation concealment (high quality in case of central, compu-
terized allocation or use of sequentially numbered sealed envelopes),
incomplete outcome (high quality if intention-to-treat analyses were
performed, and less than 10% of the outcome data were missing or
adequate imputation techniques were used), and incomplete reporting
(high quality if the outcome was reported such that the data could be
entered in the AD meta-analysis). Other potential sources of bias that
were rated were adherence (high quality if ≥80% of intervention ses-
sions were attended) and contamination (high quality in case of no or
limited adoption (< 20%) of the intervention in the control group).
Items related to blinding were omitted because blinding of patients and
personnel is difficult in case of CST. Also, the rating of blinding of
outcome assessors was excluded because anxiety and distress were as-
sessed with PROMs.
2.5. Statistical analysis
Descriptive statistics (mean, standard deviation (SD), numbers and
proportions) were used to describe the patient-, and intervention-re-
lated characteristics.
2.5.1. Aggregate data (AD) meta-analysis
Effect sizes for all individual studies included in the AD meta-ana-
lyses were calculated by subtracting the published average post-inter-
vention values of symptoms of depression and anxiety of the inter-
vention group from the values of the control group, and dividing the
result by the pooled SD of the intervention and control group (Cuijpers,
2016). When average scores or SD were not reported, we investigated
whether other statistics could be used to calculate effects sizes (i.e.,
average scores and 95% CI, between-group differences and p-values).
Studies were considered outliers if the 95% CI of the effect did not
overlap with the 95% CI of the pooled effect (Cuijpers, 2016). We
performed all AD meta-analyses with and without outliers. The het-
erogeneity was high when outlies were included, also in the subgroups
(generally I2 > 75% for depression and I2 > 60% for anxiety). We
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therefore presented the results of AD meta-analyses without outliers,
reducing the heterogeneity. All individual effect sizes were pooled in a
random effects model using Hedges g, thereby adjusting for studies with
small sample sizes (Hedges & Olkin, 1985). Using Cohen's convention,
effects of 0.2–0.49 were considered small, 0.50–0.79 as moderate and at
or above 0.8 as large (Cohen, 2013). The I2 statistic was reported as an
indicator of heterogeneity, with an I2 of 25% representing low, 50%
representing moderate and 75% representing high heterogeneity
(Higgins, Thompson, Deeks, & Altman, 2003).
Analyses of the overall effect and differences in effects between
subgroups across intervention-related moderators were conducted
using Comprehensive Meta-Analysis software (V.2.2.064). Differences
between subgroups were considered statistically significant when
p ≤ .05.
2.5.2. Individual patient data (IPD) meta-analysis
To allow pooling of the different PROMs in the IPD meta-analysis,
individual scores were recoded into z-scores by subtracting the mean
score at baseline from the individual score, then dividing the result by
the mean standard deviation per outcome measure at baseline.
Subsequently, the pooled z-scores were used for further analyses.
A one-step IPD meta-analysis was conducted to study whether pa-
tient-level characteristics moderated the effects of CST on depression
and anxiety. Linear mixed model analyses with a two-level structure (1:
patient; 2: study) were used to take into account the clustering of pa-
tients within studies by using a random intercept on study level. To
limit regression to the mean, the post-intervention value (z-scores) of
the outcome was regressed onto the intervention and adjusted for the
baseline value (z-scores). Moderators of intervention effects were
Table 1
Description of characteristics of the studies included in the individual patient data (IPD) and aggregate data (AD) meta-analyses (38 studies, n = 5246).
Study (first author, year) Country Study sample (n) Mean Age (yr) Sex
(% male)
Type of cancer PROM depression PROM
anxiety
Quality assessment
RSG AC IO IR Adh Con
Studies included in IPD meta-analysis only
Armes et al., 2007 UK 60 59 40 Mixed HADS-D HADS-A + + + + − ?
Arving et al., 2007 SWE 179 55 0 Breast HADS-D HADS-A + ? + + ? ?
Braamse et al., 2016 NL 95 54 68 Hematologic HADS-D HADS-A + + + + − +
Duijts et al., 2012 NL 212 48 0 Breast HADS-D HADS-A + + + + − ?
Ferguson et al., 2012 USA 40 50 0 Breast CES-D STAI-S + + + + ? ?
Gellaitry et al., 2010 UK 93 58 0 Breast POMS POMS + ? − − ? ?
Gielissen et al., 2006 NL 112 45 51 Mixed BDI STAI-S ? + + + ? ?
Goedendorp et al., 2010 NL 163 56 36 Mixed POMS POMS + + + − ? ?
Graves et al., 2003 USA 32 56 0 Breast POMS POMS ? ? − − ? ?
Heiney et al., 2003 USA 66 50 0 Breast POMS POMS + ? − + + ?
Johansson et al., 2008 SWE 260 64 43 Mixed HADS-D HADS-A + + ? + ? ?
Mann et al., 2012 UK 96 54 0 Breast WHQ WHQ + + + + + ?
Northouse et al., 2013 USA 484 60 39 Mixed CES-D − + + + + + +
Savard et al., 2005 CAN 57 54 0 Breast HADS-D HADS-A + ? + + + ?
van den Berg et al., 2015 NL 150 51 0 Breast HADS-D HADS-A + + + + + ?
Additional studies identified for AD meta-analysis
Aguado Loi et al., 2012 USA 220 57 20 Mixed CES-D STAI-S + + + + 0 ?
Aguado Loi et al., 2017 USA 219 55 29 Mixed CES-D STAI-S + + + + 0 ?
Badger et al., 2007 USA 75 54 0 Breast CES-D Combinationa ? ? ? + + ?
Desautels et al., 2018 CAN 62 57 0 Breast HADS-D − + + + + ? ?
Dirksen & Epstein, 2008 USA 81 58 0 Breast CES-D STAI-S + + ? + ? ?
do Carmo et al., 2017 Brazil 63 53 65 Mixed HADS-D HADS-A + + + + + −
Downe-Wamboldt et al., 2007 USA 175 62 40 Mixed CES-D − + + − + 0 ?
Garssen et al., 2013 NL 85 53 0 Breast POMS STAI-S − ? + + ? ?
Gonzalez-Fernandez et al., 2018 Spain 52 52 8 Mixed HADS-D HADS-A ? ? − + ? ?
Kangas et al., 2013 AUS 35 55 80 Head/neck BDI STAI-S ? ? + + ? ?
Kurtz et al., 2005 USA 237 55 47 Mixed CES-D − ? ? − + ? ?
Manne et al., 2017 USA 234 55 0 Gynecologic BDI − ? ? + + ? ?
Napoles et al., 2015 USA 151 51 0 Breast GSD GSD + + + + + ?
Ream et al., 2015 UK 44 53 39 Mixed HADS-D HADS-A + ? − + ? ?
Ren et al., 2019 CHN 392 47 0 Breast HAMD HAMA + + + + ? ?
Steel et al., 2016 USA 261 61 73 Mixed CES-D − + + ? + 0 ?
Stefanopoulou et al., 2015 UK 68 69 100 Prostate HADS-D HADS-A + + + + ? ?
Stoerkel et al., 2018 USA 100 ? 0 Breast PROMIS-D PROMIS-A + + − + + ?
Strong et al., 2008 UK 200 57 29 Mixed SCL-20 SCL-10 + + + + ? ?
van de Wal et al., 2017 NL 88 59 47 Mixed HADS-D HADS-A + + + + − ?
Van der Meulen et al., 2012 NL 205 60 70 Head/neck CES-D − ? + + + − +
Wells-Di Gregorio et al., 2019 USA 28 57 18 Mixed − STAI + + + + − ?
Wu et al., 2016 CHN 72 51 25 Thyroid SDS SAS ? ? − + 0 ?
Notes. The number of patients was reported at baseline. The number of patients included in the analyses might therefore differ as i.e. not all patients completed the
questionnaire.
Abbreviations: AD-MA = Aggregate Data Meta-analysis; AUS = Australia; BDI: Beck Depression Index; CAN=Canada; CES-D: Center for Epidemiologic Studies –
Depression Scale; CHN=China; DASS21 = Depression, Anxiety and Stress Scale, 21-item version, Anxiety (−A), or Depression (−D) subscale; GSD = General
Symptoms of Distress; HADS: Hospital Anxiety and Depression Scale; HAMA = Hamilton anxiety scale; HAMD = Hamilton depression rating scale; IPD-
MA = Individual Patient Data Meta-analysis; NL = The Netherlands; POMS: Profile of Mood States; PROM= Patient-reported Outcome Measure; PROMIS=Patient-
Reported Outcome Measurement Information System-57, Anxiety (−A) or Depression (−D) subscale; SAS: Self-rating Anxiety Scale; SCL: Short Checklist – originally
contains 90 questions, but here we also found shorter lists; SDS: Self-rating Depression Scale; STAI: State-Trait Anxiety Index; SWE = Sweden; UK=United Kingdom;
USA = United States of America; WHQ: Women's Health Questionnaire.
Quality assessment: += high quality; −= low quality;? = unclear quality; 0 = not applicable; RSG= random sequence generation; AC = allocation concealment;
IO = incomplete outcome; IR = incomplete reporting; Adh = adherence; Con = contamination.
a Combination of four items from the Positive and Negative Affect Schedule, one item from the Short Form-12, and three items from the Index of Clinical Stress.
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examined by subsequently adding each moderator and its interaction
term with the intervention into the regression model. The likelihood
ratio test was used to determine whether adding the interaction term
significantly improved the fit of the model. To reduce ecological bias for
patient-level interactions, within-trial interaction was separated from
between-trial interaction by centering the individual value of the cov-
ariate around the mean study value of that covariate (Helgeson, Lepore,
& Eton, 2006). Significance level of the interaction terms was set at
p ≤ .05. If adding the interaction term significantly improved the sta-
tistical model, strata were built starting with the most significant
moderator for both depression and anxiety.
Regression coefficients (β) and 95% CI are reported, which re-
present the between group difference in z-scores of depression or an-
xiety, and correspond to a Cohen's d effect size (Cohen, 2013). Statis-
tical analyses were performed using SPSS 22.0 and R Studio.
2.5.3. Representativeness of the IPD sample and publication bias
To examine whether the studies included in the IPD meta-analyses
were a representative sample of all eligible studies, we compared the
pooled effects of RCTs with IPD versus those not included using the
published data.
We also investigated publication bias for all eligible studies by in-
specting the funnel plot and calculating the effect size with a correction
for possible publication bias using Duval and Tweedie's procedure
(Duval & Tweedie, 2000). This procedure trims (removes) studies in
case of asymmetry in the funnel plot, estimates the true ‘center’ of the
funnel and replaces (fills) the omitted studies around the center. A
statistically significant dispersion between the true effect size and the
calculated effect size after correcting for possible missing studies or an
asymmetry in the funnel plot, calculated using Egger's test, could sug-
gest publication bias. A p ≤ .05 was applied as the criterion for sta-
tistical significance.
3. Results
3.1. Characteristics of studies and patients
The literature search identified 3452 references, of which 23 new
RCTs (C. X. Aguado Loi et al., 2017; Claudia X. Aguado Loi et al., 2012;
Badger, Segrin, Dorros, Meek, & Lopez, 2007; Butow et al., 2017;
Desautels, Savard, Ivers, Savard, & Caplette-Gingras, 2018; Dirksen &
Epstein, 2008; do Carmo, Paiva, de Oliveira, Nascimento, & Paiva,
2017; Downe-Wamboldt et al., 2007; Garssen et al., 2013; Gonzalez-
Fernandez, Fernandez-Rodriguez, Paz-Caballero, & Perez-Alvarez,
2018; Greer et al., 2012; Kangas, Milross, Taylor, & Bryant, 2013; Kurtz,
Kurtz, Given, & Given, 2005; Manne et al., 2017; Napoles et al., 2015;
Ream, Gargaro, Barsevick, & Richardson, 2015; Ren et al., 2019; Steel
et al., 2016; Stefanopoulou, Yousaf, Grunfeld, & Hunter, 2015; Stoerkel
et al., 2018; Strong et al., 2008; van de Wal, Thewes, Gielissen,
Speckens, & Prins, 2017; Van der Meulen et al., 2012; Wells-Di Gregorio
et al., 2019; Wu et al., 2016) were added to the 15 RCTs available in the
POLARIS database (Fig. 1). This resulted in 37 RCTs evaluating the
effects of CST on depression and 31 on anxiety (Table 1). Sample sizes
of the included studies ranged from 28 to 484 (Table 1). Of the 38
included RCTs, 17 (45%) were conducted during cancer treatment, 16
(42%) after cancer treatment, 4 (11%) included patients either during
or after cancer treatment, and 1 (2%) before and after surgery (Table 2).
In total, 25 (66%) RCTs examined interventions with face-to-face ses-
sions, 21 (55%) RCTs examined interventions that included CBT as
intervention strategy, 26 (68%) RCTs evaluated interventions with a
duration ≤12 weeks, and 17 (45%) RCTs examined interventions that
were led by a psychologist (Table 2). We identified 6 (16%) RCTs that
selected patients based on high levels of distress.
In total, 28 (74%) of the included RCTs reported random sequence
generation, 25 (66%) RCTs reported adequate allocation concealment,
25 (66%) had adequate completeness of outcome data, 35 (92%) hadTa
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Table 3
Demographic and clinical characteristics, and baseline depression and anxiety of patients included in the individual patient (IPD) meta-analysis.
Variable Control
(n = 878)
Intervention
(n = 1075)
Demographic
Age, mean (SD) years 54.7 (11.2) 55.8 (11.3)
Age categories, n (%)
< 50 years 291 (33.1) 312 (29.0)
50–70 years 493 (56.2) 615 (57.2)
≥ 70 years 92 (10.5) 147 (13.7)
Unknown 2 (0.2) 1 (0.1)
Gender, n (%)
Male 188 (21.4) 232 (21.6)
Female 690 (78.4) 843 (78.4)
Marital status, n (%)
Single/living alone 192 (21.9) 226 (21.0)
Married/living together 581 (66.2) 747 (69.5)
Unknown 105 (12.0) 102 (9.5)
Educational level, n (%)
Low/medium 384 (43.7) 429 (39.9)
High 230 (26.2) 310 (28.8)
Unknown 264 (30.1) 336 (31.3)
Clinical
Type of cancer, n (%)
Breast 595 (67.8) 705 (65.6)
Genitourinary 93 (10.6) 113 (10.5)
Gynecological 12 (1.4) 10 (0.9)
Gastrointestinal 63 (7.2) 108 (10.0)
Lung 51 (5.8) 96 (8.9)
Hematological 56 (6.4) 37 (3.4)
Other 8 (0.9) 6 (0.6)
Distant metastasis at baseline, n
(%)a
No 763 (86.9) 947 (88.1)
Yes 50 (5.7) 66 (6.1)
Unknown 65 (7.4) 62 (5.8)
Surgery, n (%)b
No 120 (13.7) 184 (17.1)
Yes 708 (80.6) 866 (80.6)
Unknown 50 (5.7) 25 (2.3)
Chemotherapy, n (%)
No 273 (31.1) 350 (32.6)
Yes 603 (68.7) 722 (67.2)
Unknown 2 (0.2) 3 (0.3)
Radiotherapy, n (%)
No 356 (40.5) 480 (44.7)
Yes 499 (56.9) 573 (53.3)
Unknown 23 (2.6) 22 (2.0)
Hormone therapy
Patients with breast cancer
(n = 1300), n (%)
No 215 (36.1) 314 (44.5)
Yes 327 (55.0) 341 (48.4)
Unknown 53 (8.9) 50 (7.1)
Patients with prostate cancer
(n = 156), n (%)
No 36 (52.2) 49 (56.3)
Yes 33 (47.8) 37 (42.6)
Unknown … 1 (1.1)
SCT, n (%)c
Allogenic SCT … …
Autologous SCT 48 (100.0) 24 (100.0)
Variable Control (n = 878) Intervention (n = 1075)
Pre mean (SD) Post mean (SD) Pre mean (SD) Post mean (SD)
Depressiond
HADS depression subscale, range 0–21 (k = 7) 4.1 (3.5) 3.6 (3.2) 4.2 (3.6) 3.4 (3.3)
CES-D total score, range (k = 2) 36.8 (12.1) 34.7 (13.0) 37.5 (9.8) 36.5 (9.8)
POMS depression subscale, range 0–60 (k = 3) 6.4 (10.5) 6.9 (10.2) 7.3 (8.6) 6.3 (7.0)
BDI total score, range 0–63 (k = 1) 8.1 (4.2) 8.7 (5.1) 11.3 (6.5) 6.4 (7.1)
WHQ depression subscale, range 0–1 (k = 1) 0.49 (0.33) 0.45 (0.31) 0.35 (0.34) 0.22 (0.24)
SCL-90 depression subscale, range 0–72 (k = 1) 21.4 (5.3) 20.4 (4.2) 21.3 (6.0) 20.3 (5.3)
Anxietyd
(continued on next page)
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complete outcome reporting, 9 (24%) described adequate intervention
adherence, and 3 (8%) provided information on contamination
(Table 1).
IPD was available for 15 RCTs (Armes et al., 2007; Arving et al.,
2007; Braamse et al., 2016; Duijts et al., 2012; Ferguson et al., 2012;
Gellaitry et al., 2010; Gielissen et al., 2006; Goedendorp et al., 2010;
Graves et al., 2003; Heiney et al., 2003; Johansson et al., 2008; Mann
et al., 2012; Northouse et al., 2013; Savard et al., 2005; van den Berg
et al., 2015) including 1953 patients with cancer, of whom 1075 were
randomly allocated to the intervention and 878 to the control group.
The mean (SD) age of patients was 55.3 (11.3) years, 78.5% were fe-
male, 68.0% were married and/or lived with a partner, 27.6% were
highly educated, 66.6% were diagnosed with breast cancer, and 5.9%
had distant metastatic disease at baseline (Table 3).
3.2. Effect of CST on depression and anxiety and intervention-related
moderators using AD meta-analyses
After removing outliers (3 RCTs for depression (Badger et al., 2007;
Desautels et al., 2018; Manne et al., 2017), 4 RCTs for anxiety (Badger
et al., 2007; Garssen et al., 2013; Kangas et al., 2013; Wells-Di Gregorio
et al., 2019), CST resulted in a statistically significant reduction in
depression (g = −0.31, 95%CI = -0.40; −0.22) and anxiety
(g = −0.32, 95%CI = -0.41; −0.24) compared to the control group
overall (Table 4). The intervention effects on depression were sig-
nificantly larger for interventions that were delivered face-to-face
compared to those delivered via other methods (p = .003), for inter-
ventions led by a psychologist (p = .02), and for studies that specifi-
cally targeted patients with high levels of psychological distress
(p = .002, Table 4). Intervention effects on anxiety seemed larger for
interventions delivered following treatment (p = .06), that were de-
livered face-to-face (p = .10), and those targeting patients with high
levels of psychological distress (p = .06), but this was not statistically
significant (Table 4). Intervention effects on depression and anxiety did
not differ significantly across subgroups for intervention strategy,
duration, and focus (Table 4).
3.3. Patient-level moderators evaluated with IPD meta-analyses
Age significantly moderated intervention effects on anxiety
(p = .02), with statistically significant effects of CST in patients
aged<50 years (β = −0.31, 95%CI = -0.44; −0.18), and
50–70 years (β = −0.11, 95%CI = -0.21; −0.00), while the effect in
patients older than 70 years was not statistically significant
(β =−0.02, 95%CI = -0.29; 0.24) (Table 5). For reference, the overall
intervention effect on anxiety based on IPD is −0.17 (95%CI =−0.25;
−0.10, Table 5).
Receiving chemotherapy significantly moderated the effect of CST
on depression (p = .03) and anxiety (p = .05): Reductions in
depression (β = −0.16, 95%CI = -0.25; −0.07) and anxiety
(β = −0.24, 95%CI = -0.33; −0.14) were statistically significant in
patients who received chemotherapy, but not in patients who did not
receive chemotherapy. No other demographic and clinical variables
significantly moderated the CST effect on depression and anxiety.
3.4. Representativeness of the IPD sample and publication bias
Pooled effects of studies with IPD on depression (p = .06) and
anxiety (p = .47) seemed somewhat smaller than the effects of studies
without IPD, but differences were not statistically significant (Table 4).
Consequently, we found no evidence that the sample of studies with IPD
was not a representative sample of published studies. The average effect
sizes, however, indicate a slightly underestimation the overall effect.
The Duvall and Tweedie's trim and fill procedure suggested that 9
trials were missing for depression and 7 trials for anxiety, resulting in
an adjusted effect size of −0.21 (95%CI = −0.31; −0.11) for de-
pression and of −0.23 (95%CI = −0.33; −0.13) for anxiety after
adjusting for possible publication bias (Table 2). The Egger's test was
statistically significant for depression (p = .04), but not for anxiety
(p = .20), indicating a presence of publication bias for depression.
4. Discussion
These AD and IPD meta-analyses showed that CST is effective in
reducing depression and anxiety in patients with cancer during and
after treatment, however, with small overall effects. The findings are in
line with results from previous meta-analyses (Cuijpers, van Straten,
Andersson, & van Oppen, 2008; Kalter et al., 2018; Sheard & Maguire,
1999). Additionally, our meta-analyses found that the effect of CST was
moderated by age and chemotherapy treatment, and by method of in-
tervention delivery, leading profession, and whether it was specifically
targeted to patients with high levels of psychological distress. These
findings have important implications to further improve CST inter-
ventions and to target interventions specifically to patients that benefit
most, thereby optimizing benefits.
The finding that CST is modestly helpful in reducing depression and
anxiety in patients with cancer, regardless of the timing of intervention
delivery in the cancer trajectory, is congruent with our previous findings
for quality of life (Kalter et al., 2018). However, this may be related to
the broader categories that we used for the analyses, or to other factors
that may have a larger influence than timing, such as whether the in-
tervention was specifically targeted to patients with distress or not, or the
specific cognitions and behaviors that were targeted by the intervention.
In contrast to previous studies that found no significant differences in
effects between face-to-face interventions and internet-based interven-
tions in reducing anxiety (Kiropoulos et al., 2008) and fatigue (Carlbring,
Andersson, Cuijpers, Riper, & Hedman-Lagerlof, 2018), we found larger
effects of face-to-face interventions on depression and we found a similar
Table 3 (continued)
Variable Control (n = 878) Intervention (n = 1075)
Pre mean (SD) Post mean (SD) Pre mean (SD) Post mean (SD)
HADS anxiety subscale, range 0–21 (k = 7) 6.3 (4.4) 5.5 (4.1) 6.2 (4.2) 4.7 (3.9)
STAI state subscale, range 20–80 (k = 2) 39.3 (9.2) 40.8 (11.0) 42.7 (9.6) 37.1 (10.7)
POMS anxiety subscale, range 0–36 (k = 3) 6.3 (6.3) 6.6 (6.7) 8.3 (6.5) 7.7 (6.4)
WHQ anxiety subscale, range 0–1 (k = 1) 0.45 (0.30) 0.41 (0.33) 0.34 (0.25) 0.23 (0.27)
SCL-90 anxiety subscale, range 0–40 (k = 1) 13.5 (4.2) 12.2 (3.3) 13.5 (3.8) 12.0 (2.9)
BDI = Beck Depression Inventory; CES-D = Center for Epidemiologic Studies – Depression scale; HADS = Hospital Anxiety and Depression Scale; k = number of
trials; n = number of patients; POMS = Profile of Mood States; SCL-90 = Symptom Checklist; SCT = stem cell transplantation; SD = standard deviation;
STAI = State Trait Anxiety Index; WHQ = Women's Health Questionnaire;
a Proportion of patients of solid tumors (n = 1881).
b Proportion of patients without SCT (n = 1881).
c Proportion of patients with SCT (n = 72).
d Higher scores represents higher level of depression and anxiety.
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trend for anxiety. Particularly interventions led by a psychologist showed
the largest benefits on depression. This indicates that, for optimal ef-
fectiveness of the intervention, it is important that the intervention is
delivered by psychologists, and preferably face-to-face. Finally, we found
that only a minority of RCTs specifically selected patients with depres-
sion or anxiety at study entry, but those that did showed substantially
larger effects. This is in line with findings from previous reviews of
studies targeting patients with higher levels of depression or anxiety at
baseline (van der Meulen et al., 2015; Williams & Dale, 2006), that
showed significantly larger reductions in depression and anxiety. It
clearly highlights that, to optimize effectiveness and cost-effectiveness of
CST, it is important to target patients that need it the most. However, our
results did not support the moderator effect of baseline depression or
anxiety, which may be explained by the low levels of depression or an-
xiety in the studies with IPD, as they were not targeted specifically to
patients with high levels of distress.
Our results did not yield any evidence that other intervention
characteristics such as intervention strategy (cognitive behavior
therapy versus other strategies like problem-solving therapy and stress
management training), or intervention focus (psychological distress
versus other outcomes like fatigue and insomnia) moderated the effects
of CST on depression and anxiety. For some analyses on potential
moderators, we needed to make broad categories for statistical power,
but the categories may have been too heterogeneous. Therefore, to gain
additional insight into which intervention characteristics are more or
less important for reducing depression and anxiety among patients with
cancer, future studies need to align study characteristics (e.g., distress
measure and eligibility criteria) or to directly compare different inter-
vention characteristics while keeping others similar.
With respect to patient-related moderators, in line with our previous
publication on quality of life (Kalter et al., 2018), the analyses on IPD
showed that younger patients had larger benefit from CST. This may be
explained by higher supportive care needs (and thus more room for
improvement) in younger patients compared to older patients (Kalter
et al., 2018; Linden, Vodermaier, MacKenzie, & Greig, 2012; O'Hea
et al., 2016; Schuurhuizen, Braamse, Konings, Verheul, & Dekker, 2019;
Simning, Conwell, Mohile, & van Wijngaarden, 2014). On the other
hand, older patients with cancer-related depression or anxiety may
have less or other specific or (supportive) care needs compared to
younger patients that are not, or only partly, met by CST (Kalter et al.,
2018). Further research is needed to identify the specific supportive
care needs of the older cancer patient population experiencing de-
pression and anxiety.
We did not observe any moderating effects of sex in our study. This
is in line with our IPD meta-analyses focusing on quality of life (Kalter
et al., 2018). Overall, findings of previous descriptive studies have been
mixed. Some studies report that depression (Albert, 2015; Hong & Tian,
2014) and anxiety (Linden et al., 2012) are generally more prevalent in
women than in men, and therefore, women could benefit more from
these interventions. However, another study among patients with var-
ious cancer types found that men more often experience anxiety than
women (Hong & Tian, 2014).
In line with our previous meta-analysis on quality of life, our study
found a moderator effect of chemotherapy, where patients who received
chemotherapy experienced larger reductions in depression and anxiety
after CST compared to those who did not. This may be related to higher
levels of depression and anxiety associated with chemotherapy (Kyranou
et al., 2014; Yang et al., 2016). As hormone therapy has also been as-
sociated with increased levels of depression and anxiety (Sharpley,
Christie, & Bitsika, 2014), larger effects of CST were also expected in
patients who received hormone therapy as part of their treatment com-
pared to those who did not. This, however, did not prove to be the case in
our study. The lack of moderator effects of other treatment types may
result from our dichotomisation of each treatment into whether patients
received treatment or not, which does not take into account the intensity
of treatment. Due to the differences in data collected and provided by the
original studies, we were unable to specify types of surgery (e.g., mas-
tectomy or lumpectomy), or types of chemotherapy, radiotherapy or
hormone therapy in further detail. Since the cancer diagnosis and its
treatment are closely related, the effect of treatment types should be
examined within more homogenous groups of patients.
5. Strengths and limitations
A strength of this study is that AD and IPD meta-analyses were
combined which provided us the unique opportunity to use the ad-
vantages of both approaches. The strength of the AD meta-analysis is
the ability to include a larger number of RCTs compared with an IPD
meta-analysis, which provided a larger database to test differences in
intervention characteristics at the study level. In addition, the strength
of the IPD-meta-analysis is the ability to test demographic, clinical, and
psychosocial characteristics as effect moderators at the patient level
Table 5
Effects of CST on depression and anxiety, stratified by potential patient-level moderator subgroups, based on IPD meta-analyses (15 studies).
Effects of CST Depression β (95% CI) χ2 [df], p-value Anxiety β (95% CI) χ2 [df], p-value
−0.12 (−0.19; −0.05)⁎ −0.17 (−0.25; −0.10)⁎
Age, years 2.37 [1], 0.12 5.14 [1], 0.02⁎
Age categories
< 50 years … −0.31 (−0.44; −0.18)⁎
50–70 years … −0.11 (−0.21; −0.00)⁎
≥70 years … −0.02 (−0.29; 0.24)
Gender 1.50 [1], 0.22 0.79 [1], 0.37
Marital status 0.35 [1], 0.55 0.69 [1], 0.41
Education level 0.29 [1], 0.59 0.03 [1], 0.86
Type of cancer 2.49 [6], 0.87 5.08 [6], 0.53
Distant metastasis at baseline 0.18 [1], 0.67 1.79 [1], 0.18
Baseline value of outcomea 1.84 [1], 0.18 0.99 [1], 0.32
Surgery 0.46 [1], 0.50 1.98 [1], 0.16
Chemotherapy 4.50 [1], 0.03⁎ 3.85 [1], 0.05⁎
No −0.05 (−0.17; 0.07) −0.08 (−0.21; 0.05)
Yes −0.16 (−0.25; −0.07)⁎ −0.24 (−0.33; −0.14)⁎
Radiotherapy 0.09 [1], 0.76 0.44 [1], 0.50
Hormone Breast 0.10 [1], 0.75 0.02 [1], 0.89
Hormone Prostate 0.96 [1], 0.33 2.58 [1], 0.11
Regression coefficients (β), 95% confidence intervals (CI), and Chi-square test with corresponding degrees of freedom and p-values are presented.
⁎ p < .05.
a Baseline depression as moderator for outcome depression, baseline anxiety as moderator for outcome anxiety.
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using a large sample, and to conduct stratified analyses with sufficient
power. However, although we maximised power for each analyses by
combining both types of meta-analyses, some study-level moderators
may still have been underpowered due to small subgroups, or loss of
information by forming subgroups.
A limitation of IPD meta-analysis is the need to obtain the original
data for an RCT to be included in the analysis. This may result in re-
trieval bias, since IPD can often only be obtained from a subset of
studies. However, there was no significant difference in effects between
studies with and without IPD, indicating our IPD sample was re-
presentative of the studies identified in the AD meta-analysis.
Nevertheless, overall, there seemed to be a publication bias for de-
pression; studies with larger effects on depression appeared more likely
to be published, which may have resulted in an overestimation of the
effect of CST on depression. Other possible biases that may have been
present in the RCTs under investigation could be related to the absence
of information on adherence to the intervention and potential con-
tamination of the control group. Finally, our investigation was limited
to the short-term intervention effects of CST as very few RCTs examined
longer term effects. Research into long-term effects of CSI for depres-
sion and anxiety is therefore warranted.
In conclusion, CST significantly reduces symptoms of depression
and anxiety during and after cancer treatment; however, the overall
effects are small, and possibly of limited clinical relevance. CST effects
were significantly larger in patients who were younger, and received
chemotherapy as part of their cancer treatment, as well as in studies in
which the intervention was delivered face to face and by a psychologist.
Significant and clinically meaningful benefits can be obtained by tar-
geting patients with high levels of psychological distress. Further re-
search is needed to unravel differences in effects between different in-
tervention-characteristics in more detail.
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Appendix A. Search terms used in pubmed search
#1 neoplasms
“neoplasms”[Mesh] OR metastas*[tiab] OR neoplas* [tiab] OR tu-
mor*[tiab] OR cancer*[tiab] OR.
tumor[tiab] OR tumora*[tiab] OR tumorb*[tiab] OR tumorc*[tiab]
OR tumord*[tiab] OR tumore*[tiab] OR tumorf*[tiab] OR tu-
morg*[tiab] OR tumorh*[tiab] OR tumori*[tiab] OR tumork*[tiab] OR
tumorl*[tiab] OR tumorm*[tiab] OR tumorn*[tiab] OR tumoro*[tiab]
OR tumorp*[tiab] OR tumorr*[tiab] OR tumors*[tiab] OR tu-
mort*[tiab] OR tumoru*[tiab] OR tumorv*[tiab] OR tumorw*[tiab] OR
tumorx*[tiab] OR tumory*[tiab] OR tumorz*[tiab] OR tumor’*[tiab]
OR tumor1[tiab].
#2 psychosocial therapy
“Social Support”[Mesh] OR “Behavior Therapy”[Mesh] OR “cogni-
tive therapy”[Mesh] OR “Mind-body therapies”[Mesh] OR “relaxation
therapy”[Mesh] OR “counseling”[Mesh] OR “biofeedback,
psychology”[Mesh] OR “guideline adherence”[Mesh] OR “patient
compliance”[Mesh] OR “patient education as topic”[Mesh] OR “Health
promotion”[Mesh] OR “Health education”[Mesh] OR “health
behavior”[Mesh] OR “Reinforcement (Psychology)”[Mesh] OR “social
support”[tiab] OR “Behavior therapy”[tiab] OR “cognitive ther-
apy”[tiab] OR “Mind-body therapies”[tiab] OR counselor* [tiab] OR
“psychology biofeedback”[tiab] OR “guideline adherence”[tiab] OR
“patient compliance”[tiab] OR “patient education as topic”[tiab] OR
“Health promotion”[tiab] OR “Health education”[tiab] OR “health
behavior”[tiab] OR “Reinforcement (Psychology)”[tiab] OR alternative
therap*[tiab] OR “Psychophysiology”[tiab] OR “behavior trai-
ning”[tiab] OR “behavior treatment”[tiab] OR “desensitization”[tiab]
OR “CBT”[tiab] OR cognitive behavior therap*[tiab] OR cognitive be-
havior treatment*[tiab] OR cognitive behavioural therap*[tiab] OR
cognitive behavioural treatment*[tiab] OR cognitive behavior ther-
ap*[tiab] OR cognitive behavior treatment*[tiab] OR cognitive beha-
vioural therap*[tiab] OR cognitive behavioural treatment*[tiab] OR
“anthroposophy”[tiab] OR “complementary medicine”[tiab] OR com-
plementary therap*[tiab] OR mind-body relation*[tiab] OR mind-body
therap*[tiab] OR mind body techniq*[tiab] OR mind body ther-
ap*[tiab] OR “naturopathy orthomolecular medicine”[tiab] OR polarity
thera*[tiab] OR reflexotherap*[tiab] OR spiritual therap*[tiab] OR
“mind-body and relaxation techniques”[tiab] relaxation therap*[tiab]
OR client centered therap*[tiab] OR nondirective therap*[tiab] OR
“biofeedback (psychology)”[tiab] OR psychoneuroimmunolog*[tiab]
OR psychophysiologic respons*[tiab] OR “patient adherence”[tiab] OR
“treatment compliance”[tiab] OR health behav*[tiab] OR health pro-
moting behav*[tiab] OR health related behav*[tiab] OR “con-
ditioning”[tiab] OR “differential reinforcement”[tiab] OR “knowledge
of results (psychology)” [tiab].
#3 Outcome measures
depressive OR anxiety OR distress.
#4 Randomized controlled trials
“randomized controlled trial”[pt] OR “controlled clinical trial”[pt]
OR “randomized controlled trials”[mh] OR “random allocation” [mh]
OR “double-blind method” [mh] OR “single-blind method” [mh] OR
“clinical trial” [pt] OR “clinical trials” [mh] OR “clinical trial” [tw] OR
((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND
(mask* [tw] OR blind* [tw])) OR “latin square” [tw] OR placebos [mh]
OR placebo* [tw] OR random* [tw] OR research design [mh:noexp] OR
comparative study [pt] OR evaluation studies [pt] OR follow-up studies
[mh] OR prospective studies [mh] OR cross-over studies [mh] OR
control[tw] OR controll*[tw] OR prospectiv* [tw] OR volunteer* [tw])
NOT (animal [mh] NOT human [mh]).
(RCT Filter kort: “randomized controlled trial”[pt] OR “controlled
clinical trial”[pt] OR “randomized”[tiab] OR “placebo”[tiab] OR “drug
therapy”[sh] OR “randomly”[tiab] OR “trial”[tiab] OR “groups”[tiab])
#5 Adult (not child)
((“Adolescent”[Mesh] OR “Child”[Mesh] OR “Infant”[Mesh] OR
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adolescen*[tiab] OR child*[tiab] OR schoolchild*[tiab] OR in-
fant*[tiab] OR girl*[tiab] OR boy*[tiab] OR teen[tiab] OR teens[tiab]
OR teenager*[tiab] OR youth*[tiab] OR pediatr*[tiab] OR pae-
diatr*[tiab] OR puber*[tiab]) NOT (“Adult”[Mesh] OR adult*[tiab] OR
man[tiab] OR men[tiab] OR woman[tiab] OR women[tiab]))
References
Aguado Loi, C. X., Nesman, T. M., Xu, P., Taylor, T. R., McMillan, S., Krischer, J. P., ...
Huegel, V. (2017). A self-administered stress management intervention for hispanic
patients undergoing cancer chemotherapy. Journal of Immigrant and Minority Health,
19, 1121–1131.
Aguado Loi, C. X., Taylor, T. R., McMillan, S., Gross-King, M., Xu, P., & Shoss, M. K.
(2012). Use and helpfulness of self-administered stress management therapy in pa-
tients undergoing cancer chemotherapy in community clinical settings. Journal of
Psychosocial Oncology, 30.
Albert, P. R. (2015). Why is depression more prevalent in women? Journal of Psychiatry &
Neuroscience, 40.
Andersson, G., & Cuijpers, P. (2009). Internet-based and other computerized psycholo-
gical treatments for adult depression: a meta-analysis. Cognitive Behaviour Therapy,
38, 196–205.
Armes, J., Chalder, T., Addington-Hall, J., Richardson, A., & Hotopf, M. (2007). A ran-
domized controlled trial to evaluate the effectiveness of a brief, behaviorally oriented
intervention for cancer-related fatigue. Cancer, 110, 1385–1395.
Arrieta, O., Angulo, L. P., Nunez-Valencia, C., Dorantes-Gallareta, Y., Macedo, E. O.,
Martinez-Lopez, D., ... Onate-Ocana, L. F. (2013). Association of depression and an-
xiety on quality of life, treatment adherence, and prognosis in patients with advanced
non-small cell lung cancer. Annals of Surgical Oncology, 20, 1941–1948.
Arving, C., Sjöden, P., Bergh, J., Hellbom, M., Johansson, B., Glimelius, B., & Brandberg,
Y. (2007). Individual psychosocial support for breast cancer patients. Cancer Nursing,
30, E10–E19.
Badger, T., Segrin, C., Dorros, S., Meek, P., & Lopez, A. (2007). Depression and anxiety in
women with breast cancer and their partners. Nursing Research, 56, 44–53.
Badger, T., Segrin, C., Figueredo, A., Harrington, J., Sheppard, K., Passalacqua, S., ...
Bishop, M. (2013). Who benefits from a psychosocial counselling versus educational
intervention to improve psychological quality of life in prostate cancer survivors?
Psychology & Health, 28, 336–354.
Ballesio, A., Aquino, M., Feige, B., Johann, A., Kyle, S., Spiegelhalder, K., ... Baglioni, C.
(2017). The effectiveness of behavioural and cognitive behavioural therapies for
insomnia on depressive and fatigue symptoms: A systematic review and network
meta-analysis. Sleep Medicine Reviews, 1–16.
Barber, B., Dergousoff, J., Nesbitt, M., Mitchell, N., Harris, J., O'Connell, D., ... Seikaly, H.
(2015). Depression as a predictor of postoperative functional performance status
(PFPS) and treatment adherence in head and neck cancer patients: a prospective
study. Journal of Otolaryngology - Head & Neck Surgery, 44, 38.
Barsevick, A. M., Irwin, M., Hinds, P., Miller, A., Berger, A., Jacobsen, P., ... Cella, D.
(2013). Recommendations for high-priority research on cancer-related fatigue in
children and adults. Journal of the National Cancer Institute, 105, 1432–1440.
van den Berg, S., Gielissen, M., Custers, J., van der Graaf, W., Ottevanger, P., & Prins, J.
(2015). BREATH: Web-based self-management for psychological adjustment after
primary breast cancer - Results of a multicenter randomized controlled trial. Journal
of Clinical Oncology, 33, 2763–2771.
Berlin, J., Santanna, J., Schmid, C., Szczech, L., & Feldman, H. (2002). Individual patient-
versus group-level data meta-regressions for the investigation of treatment effect
modifiers: ecological bias rears its ugly head. Statistics in Medicine, 21, 371–387.
van den Beuken-van Everdingen, M., Hochstenback, L., Joosten, E., Tjan-Heijnen, V., &
Janssen, D. (2016). Update on prevalence of pain in patients with cancer: systematic
review and meta-analysis. Journal of Pain and Symptom Management, 51, 1070–1090.
Braamse, A., van Meijel, B., Visser, O., Boenink, A., Cuijpers, P., Eeltink, C., ... Dekker, J.
(2016). A randomized clinical trial on the effectiveness of an intervention to treat
psychological distress and improve quality of life after autologous stem cell trans-
plantation. Annals of Hematology, 95, 105–114.
Buffart, L., Kalter, J., Chinapaw, M., Heymans, M., Aaronson, N., Courneya, K., ... Brug, J.
(2013). Predicting OptimaL cAncer RehabIlitation and Supportive care (POLARIS):
rationale and design for meta-analyses of individual patient data of randomized
controlled trials that evaluate the effect of physical activity and psychosocial inter-
ventions on health-related quality of life in cancer survivors. Systematic Reviews, 2.
Buffart, L., Kalter, J., Sweegers, M., Courneya, K., Newton, R., Aaronson, N., ... Brug, J.
(2017). Effects and moderators of exercise on quality of life and physical function in
patients with cancer: An individual patient data meta-analysis of 34 RCTs. Cancer
Treatment Reviews, 52, 91–104.
Butow, P. N., Turner, J., Gilchrist, J., Sharpe, L., Smith, A. B., Fardell, J. E., ... Thewes, B.
(2017). Randomized trial of conquerfear: a novel, theoretically based psychosocial
intervention for fear of cancer recurrence. Journal of Clinical Oncology, 35,
4066–4077.
Carlbring, P., Andersson, G., Cuijpers, P., Riper, H., & Hedman-Lagerlof, E. (2018).
Internet-based vs. face-to-face cognitive behavior therapy for psychiatric and somatic
disorders: an updated systematic review and meta-analysis. Cognitive Behaviour
Therapy, 47, 1–18.
Cleeland, C., Mendoza, T., Wang, X., Chou, C., Harle, M., Morrissey, M., & Engstorm, M.
(2000). Assessing symptom distress in cancer patients: the M.D. Anderson symptom
inventory. Cancer, 89, 1634–1646.
Cohen, J. (2013). Statistical Power Analysis for the Behavioral Sciences (ed Revised edition).
Academic press.
Courneya, K., & Friedenreich, C. (2007). Physical activity and cancer control. Seminars in
Oncology Nursing, 23, 242–252.
Cuijpers, P. (2016). Meta-analysis in mental health research. A pratical guide. Amsterdam:
VU University Amsterdam.
Cuijpers, P., van Straten, A., Andersson, G., & van Oppen, P. (2008). Psychotherapy for
depression in adults: a meta-analysis of comparative outcome studies. Journal of
Consulting and Clinical Psychology, 76, 909–922.
Cunningham, A. (1995). Group psychological therapy for cancer patients. A brief dis-
cussion of indications for its use, and the range of interventions available. Support
Care Cancer, 3, 244–247.
Dauchy, S., Dolbeault, S., & Reich, M. (2013). Depression in cancer patients. European
Journal of Cancer Care, 11, 205–215.
Desautels, C., Savard, J., Ivers, H., Savard, M. H., & Caplette-Gingras, A. (2018).
Treatment of depressive symptoms in patients with breast cancer: A randomized
controlled trial comparing cognitive therapy and bright light therapy. Health
Psychology, 37, 1–13.
Dirksen, S., & Epstein, D. (2008). Efficacy of an insomnia intervention on fatigue, mood
and quality of life in breast cancer survivors. Journal of Advanced Nursing, 61,
664–675.
do Carmo, T. M., Paiva, B. S. R., de Oliveira, C. Z., Nascimento, M. S. A., & Paiva, C. E.
(2017). The feasibility and benefit of a brief psychosocial intervention in addition to
early palliative care in patients with advanced cancer to reduce depressive symptoms:
a pilot randomized controlled clinical trial. BMC Cancer, 17, 564.
Downe-Wamboldt, B. L., Butler, L. J., Melanson, P. M., Coulter, L. A., Singleton, J. F.,
Keefe, J. M., & David, G. (2007). The effects and expense of augmenting usual cancer
clinic care with telephone problem-solving counseling. Cancer Nursing, 30, 441–453.
Duijts, S. F., van Beurden, M., Oldenburg, H. S., Hunter, M. S., Kieffer, J. M., Stuiver, M.
M., Gerritsma, M. A., Menke-Pluymers, M. B., Plaisier, P. W., Rijna, H., Lopes
Cardozo, A. M., Timmers, G., van der Meij, S., van der Veen, H., Bijker, N., de Widt-
Levert, L. M., Geenen, M. M., Heuff, G., van Dulken, E. J., Boven, E., & Aaronson, N.
K. (2012). Efficacy of cognitive behavioral therapy and physical exercise in alle-
viating treatment-induced menopausal symptoms in patients with breast cancer: re-
sults of a randomized, controlled, multicenter trial. J Clin Oncol. 30(33), 4124–4133.
Duval, S., & Tweedie, R. (2000). Trim and fill: A simple funnel-plot-based method of
testing and adjusting for publication bias in meta-analysis. Biometrics, 56, 455–463.
Faller, H., Schuler, M., Richard, M., Heckl, U., Weis, J., & Küffner, R. (2013). Effects of
psycho-oncologic interventions on emotional distress and quality of life in adult
patients with cancer: systematic review and meta-analysis. Journal of Clinical
Oncology, 31, 782–793.
Ferguson, R., McDonald, B., Rocque, M., Furstenberg, C., Horrigan, S., Ahles, T., & Saykin,
A. (2012). Development of CBT for chemotherapy-related cognitive change: results of
a waitlist control trial. Psychooncology, 21, 176–186.
Garssen, B., Boomsma, M. F., De Jager Meezenbroek, E., Porsild, T., Berkhof, J., Berbee,
M., ... Beelen, R. H. J. (2013). Stress management training for breast cancer surgery
patients. Psycho-Oncology, 22, 572–580.
Gellaitry, G., Peters, K., Bloomfield, D., & Horne, R. (2010). Narrowing the gap: the effects
of an expressive writing intervention on perceptions of actual and ideal emotional
support in women who have completed treatment for early stage breast cancer.
Psychooncology, 19, 77–84.
Gielissen, M., Verhagen, S., Witjes, F., & Bleijenberg, G. (2006). Effects of cognitive be-
havior therapy in severely fatigued disease-free cancer patients compared with pa-
tients waiting for cognitive behavior therapy: A randomized controlled trial. Journal
of Clinical Oncology, 24, 4882–4887.
Goedendorp, M. M., Peters, M. E. W. J., Gielissen, M., Witjes, J. A., Leer, J. W., Verhagen,
C. A., & Blijenberg, G. (2010). Is increasing physical activity necessary to diminish
fatigue during cancer treatment? Comparing cognitive behavior therapy and a brief
nursing intervention with usual care in a multicenter randomized controlled trial.
Oncologist, 15, 1122–1132.
Gonzalez-Fernandez, S., Fernandez-Rodriguez, C., Paz-Caballero, M. D., & Perez-Alvarez,
M. (2018). Treating anxiety and depression of cancer survivors: Behavioral activation
versus acceptance and commitment therapy. Psicothema, 30, 14–20.
Graves, K., Carter, C., Anderson, E., & Winett, R. (2003). Quality of life pilot intervention
for breast cancer patients: Use of social cognitive theory. Palliative & Supportive Care,
1, 121–134.
Greer, J. A., Traeger, L., Bemis, H., Solis, J., Hendriksen, E. S., Park, E. R., ... Safren, S. A.
(2012). Pilot randomized controlled trial of brief cognitive-behavioral therapy for
anxiety in patients with terminal cancer. Oncologist, 17, 1337–1345.
Guo, Z., Tang, H., Li, H., Feng, K., Huang, Y., Bu, Q., & Jiang, W. (2013). The benefits of
psychosocial interventions for cancer patients undergoing radiotherapy. Health and
Quality of Life Outcomes, 11.
Hedges, L., & Olkin, I. (1985). Statistical Method for Meta-Analysis. San Diego, CA:
Academic press.
Heiney, S., McWayne, J., Hurley, T., Lamb, L., Bryant, L., Butler, W., & Godder, K. (2003).
Efficacy of therapeutic group by telephone for women with breast cancer. Cancer
Nursing, 26, 439–447.
Helgeson, V., Lepore, S., & Eton, D. (2006). Moderators of the benefits of psychoeduca-
tional interventions for men with prostate cancer. Health Psychology, 25, 348–354.
Heron-Speirs, H., Baken, D., & Harvey, S. (2012). Moderators of psycho-oncology therapy
effectiveness: Meta-analysis of socio-demographic and medical patient character-
istics. Clinical Psychology: Science and Practice, 19, 402–416.
Heron-Speirs, H., Harvey, S., & Baken, D. (2013). Moderators of psycho-oncology therapy
effectiveness: meta-analysis of therapy characteristics. Journal of Psychosocial
Oncology, 31, 617–641.
Higgins, J., Thompson, S., Deeks, J., & Altman, D. (2003). Measuring inconsistency in
meta-analyses. BMJ, 327, 557–560.
L.M. Buffart, et al. Clinical Psychology Review 80 (2020) 101882
13
Higgins, J. P., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., ...
Cochrane Statistical Methods, G. (2011). The Cochrane Collaboration’s tool for as-
sessing risk of bias in randomised trials. BMJ, 343, d5928.
Hong, J. S., & Tian, J. (2014). Prevalence of anxiety and depression and their risk factors
in Chine cancer patients. Support Care Cancer, 22, 452–459.
Hutter, N., Vogel, B., Alexander, T., Baumeister, H., Helmes, A., & Bengel, J. (2013). Are
depression and anxiety determinants or indicators of quality of life in breast cancer
patients? Psychology, Health & Medicine, 18, 412–419.
Jacobsen, P., & Jim, H. (2008). Psychosocial interventions for anxiety and depression in
adult cancer patients: Achievements and Challenges. CA: a Cancer Journal for
Clinicians, 58, 214–230.
Johansson, B., Brandberg, Y., Hellbom, M., Persson, C., Petersson, L., Berglund, G., &
Glimelius, B. (2008). Health-related quality of life and distress in cancer patients:
results from a large randomised study. British Journal of Cancer, 99, 1975–1983.
Kalter, J., Sweegers, M. G., Verdonck-de Leeuw, I. M., Brug, J., & Buffart, L. M. (2019).
Development and use of a flexible data harmonization platform to facilitate the
harmonization of individual patient data for meta-analyses. BMC Research Notes, 12,
164.
Kalter, J., Verdonck-de Leeuw, I. M., Sweegers, M. G., Aaronson, N. K., Jacobsen, P. B.,
Newton, R. U., ... Buffart, L. M. (2018). Effects and moderators of psychosocial in-
terventions on quality of life, and emotional and social function in patients with
cancer: An individual patient data meta-analysis of 22 RCTs. Psychooncology, 27,
1150–1161.
Kangas, M., Milross, C., Taylor, A., & Bryant, R. (2013). A pilot randomized controlled
trial of a brief early intervention for reducing posttraumatic stress disorder, anxiety
and depressive symptoms in newly diagnosed head and neck cancer patients. Psycho-
Oncology, 22, 1665–1673.
Kiropoulos, L. A., Klein, B., Austin, D. W., Gilson, K., Pier, C., Mitchell, J., & Ciechomski,
L. (2008). Is Internet-based CBT for panic disorder and agoraphobia as effective as
face-to-face CBT? Journal of Anxiety Disorders, 22, 1273–1284.
Krebber, A., Buffart, L., Kleijn, G., Riepma, I., de Bree, R., Leemans, C., ... Verdonck-de
Leeuw, I. (2014). Prevalence of depression in cancer patients: a meta-analysis of
diagnostic interviews and self-report instruments. Psychooncology, 23, 121–130.
Kurtz, M. E., Kurtz, J. C., Given, C. W., & Given, B. (2005). A randomized, controlled trial
of a patient/caregiver symptom control intervention: Effects on depressive sympto-
matology of caregivers of cancer patients. Journal of Pain and Symptom Management,
30, 112–122.
Kyranou, M., Puntillo, K., Aouizerat, B. E., Paul, S. M., Cooper, B. A., West, C., ... Elboim,
C. (2014). Trajectories of depressive symptoms in women prior to and for 6 months
after breast cancer surgery. Journal of Applied Biobehavioral Research, 19, 79–105.
Linden, W., Vodermaier, A., MacKenzie, R., & Greig, D. (2012). Anxiety and depression
after cancer diagnosis: prevalence rates by cancer type, gender, and age. Journal of
Affective Disorders, 141, 343–351.
Lyman, G. H., & Kuderer, N. M. (2005). The strengths and limitations of meta-analyses
based on aggregate data. BMC Medical Research Methodology, 5.
Mann, E., Smith, M., Hellier, J., Balabanovic, J., Hamed, H., Grunfeld, E., & Hunter, M.
(2012). Cognitive behavioural treatment for women who have menopausal symptoms
after breast cancer treatment (MENOS 1): a randomised controlled trial. The Lancet
Oncology, 13, 309–318.
Manne, S. L., Virtue, S. M., Ozga, M., Kashy, D., Heckman, C., Kissane, D. W., ...
Rodriquez, L. (2017). A comparison of two psychological interventions for newly-
diagnosed gynecological cancer patients. Gynecologic Oncology, 144, 354–362.
Matthews, H., Grunfeld, E., & Turner, A. (2016). The efficacy of interventions to improve
psychosocial outcomes following surgical treatment for breast cancer: a systematic
review and meta-analysis. Psycho-Oncology, 26, 593–607.
van der Meulen, I. C., May, A. M., Rob, J., de Leeuw, J., Koole, R., Oosterom, M., ... Ros,
W. (2015). Moderators of the response to a nurse-led psychosocial intervention to
reduce depressive symptoms in head and neck cancer patients. Support Care Cancer,
23, 2417–2426.
Mitchell, A., Chan, M., Bhatti, H., Halton, M., Grassi, L., Johansen, C., & Meader, N.
(2011). Prevalence of depression, anxiety, and adjustment disorder in oncological,
haematological, and palliative-care settings: a meta-analysis of 94 interview-based
studies. The Lancet Oncology, 12, 160–174.
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. (2009). Preferred reporting items for
systematic reviews and meta-analyses: The PRISMA statement. PLoS Medicine, 6.
Napoles, A., Ortiz, C., Santoyo-Olsson, J., Stewart, A. L., Gregorich, S., Lee, H. E., ... Luce,
J. (2015). Nuevo Amanecer: results of a randomized controlled trial of a community-
based, peer-delivered stress management intervention to improve quality of life in
Latinas with breast cancer. American Journal of Public Health, 105, e55–e63.
Nikbakhsh, N., Moudi, S., Abbasian, S., & Khafri, S. (2014). Prevalence of depression and
anxiety among cancer patients. Caspian Journal of Internal Medicine, 5, 167–170.
Northouse, L., Mood, D., Schafenacker, A., Kalemkerian, G., Zalupski, M., LoRusso, P., ...
Kershaw, T. (2013). Randomized clinical trial of a brief and extensive dyadic inter-
vention for advanced cancer patients and their family caregivers. Psychooncology, 22,
555–563.
O’Hea, E. L., Monahan, B. R., Cutillo, A., Person, S. D., Grissom, G., & Boudreaux, E. D.
(2016). Predictors of psychological distress and interest in mental health services in
individuals with cancer. Journal of Health Psychology, 21, 1145–1156.
Pirl, W. (2004). Evidence report on the occurrence, assessment, and treatment of
depression in cancer patients. Journal of the National Cancer Institute. Monographs, 32.
Ream, E., Gargaro, G., Barsevick, A. M., & Richardson, A. (2015). Management of cancer-
related fatigue during chemotherapy through telephone motivational interviewing:
modeling and randomized exploratory trial. Patient Education and Counseling, 98,
199–206.
Ren, W., Qiu, H., Yang, Y., Zhu, X., Zhu, C., Mao, G., ... He, J. (2019). Randomized
controlled trial of cognitive behavioural therapy for depressive and anxiety symp-
toms in Chinese women with breast cancer. Psychiatry Research, 271, 52–59.
Riley, R., Lambert, P., & Abo-Zaid, G. (2010). Meta-analysis of individual participant
data: rationale, conduct and reporting. BMJ, 340.
Savard, J., Simard, S., Ivers, H., & Morin, C. (2005). Randomized study on the efficacy of
cognitive-behavioral therapy for insomnia secondary to breast cancer, part I: Sleep
and psychological effects. Journal of Clinical Oncology, 23, 6083–6096.
Schneider, S., Moyer, A., Knapp-Oliver, S., Sohl, S., Cannella, D., & Targhetta, V. (2010).
Pre-intervention distress moderates the efficacy of psychosocial treatment for cancer
patients: a meta-analysis. Journal of Behavioral Medicine, 33, 1–14.
Schuurhuizen, C., Braamse, A. M. J., Konings, I., Verheul, H. M. W., & Dekker, J. (2019).
Predictors for use of psychosocial services in patients with metastatic colorectal
cancer receiving first line systemic treatment. BMC Cancer, 19, 115.
Sharpley, C., Christie, D., & Bitsika, V. (2014). Do hormone treatments for prostate cancer
cause anxiety and depression? International Journal of Clinical Oncology, 19, 523–530.
Sheard, T., & Maguire, P. (1999). The effect of psychological interventions on anxiety and
depression in cancer patients: results of two meta-analyses. British Journal of Cancer,
80, 1770–1780.
Simning, A., Conwell, Y., Mohile, S. G., & van Wijngaarden, E. (2014). The moderating
effect of age on the 12-month prevalence of anxiety and depressive disorders in adults
with a lifetime history of cancer. The American Journal of Geriatric Psychiatry, 22,
1399–1409.
Spek, V., Cuijpers, P., Nyklicek, I., Riper, H., Keyzer, J., & Pop, V. (2007). Internet-based
cognitive behaviour therapy for symptoms of depression and anxiety: a meta-ana-
lysis. Psychological Medicine, 37, 319–328.
Steel, J. L., Geller, D. A., Kim, K. H., Butterfield, L. H., Spring, M., Grady, J., ... Tsung, A.
(2016). Web-based collaborative care intervention to manage cancer-related symp-
toms in the palliative care setting. Cancer, 122, 1270–1282.
Stefanopoulou, E., Yousaf, O., Grunfeld, B., & Hunter, M. (2015). A randomised controlled
trial of a brief cognitive behavioural intervention for men who have hot flushes
following prostate cancer treatment (MANCAN). Psycho-Oncology, 24, 1159–1166.
Stewart, L., & Tierney, J. (2002). To IPD or not to IPD? Advantages and disadvantages of
systematic reviews using individual patient data. Evaluation & the Health Professions,
25, 76–97.
Stoerkel, E., Bellanti, D., Paat, C., Peacock, K., Aden, J., Setlik, R., ... Inman, A. (2018).
Effectiveness of a self-care toolkit for surgical breast cancer patients in a military
treatment facility. Journal of Alternative and Complementary Medicine, 24, 916–925.
Strong, V., Waters, R., Hibberd, C., Murray, G., Wall, L., Walker, J., ... Sharpe, M. (2008).
Management of depression for people with cancer (SMaRT oncology 1): a randomised
trial. The Lancet Oncology, 372, 40–48.
Tierney, J., Vale, C., Riley, R., Smith, C., Stewart, L., Clarke, M., & Rovers, M. (2015).
Individual Participant Data (IPD) meta-analyses of randomised controlled trials:
guidance on their use. PLoS Medicine, 12.
Van der Meulen, I. C., May, A. M., Ros, W., Oosterom, M., Hordijk, G.-J., Koole, R., & de
Leeuw, J. R. J. (2012). One-year effect of a nurse-led psychosocial intervention on
depressive symptoms in patients with head and neck cancer: a randomized controlled
trial. The Oncologist, 18, 336–344.
van de Wal, M., Thewes, B., Gielissen, M. F. M., Speckens, A., & Prins, J. B. (2017).
Efficacy of blended cognitive behavior therapy for high fear of recurrence in breast,
prostate, and colorectal cancer survivors: The SWORD study, a randomized con-
trolled trial. Journal of Clinical Oncology, 36.
Wells-Di Gregorio, S. M., Marks, D. R., DeCola, J., Peng, J., Probst, D., Zaleta, A., ...
Magalang, U. (2019). Pilot randomized controlled trial of a symptom cluster inter-
vention in advanced cancer. Psychooncology, 28, 76–84.
Willems, R. A., Mesters, I., Lechner, L., Kanera, I. M., & Bolman, C. A. W. (2017). Long-
term effectiveness and moderators of a web-based tailored intervention for cancer
survivors on social and emotional functioning, depression, and fatigue: randomized
controlled trial. Journal of Cancer Survivorship, 11, 691–703.
Williams, S., & Dale, J. (2006). The effectiveness of treatment for depression/depressive
symptoms in adults with cancer: a systematic review. British Journal of Cancer, 94,
372–390.
Wu, H., Zhong, H., Xu, Y., Xu, C., Zhang, Y., & Zhang, W. (2016). Psychological and
behavioral intervention improves the quality of life and mental health of patients
suffering from differentiated thyroid cancer treated with postoperative radioactive
iodine-131. Neuropsychiatric Disease and Treatment, 12.
Yang, H., Brand, J. S., Fang, F., Chiesa, F., Johansson, A. L. V., Hall, P., & Czene, K.
(2016). Time-dependent risk of depression, anxiety, and stress-related disorders in
patients with invasive and in situ breast cancer. International Journal of Cancer, 140,
841–852.
Zhu, L., Ranchor, A., van der Lee, M., Garssen, B., Almansa, J., Sanderman, R., &
Schrovers, M. (2017). Co-morbidity of depression, anxiety and fatigue in cancer
patients receiving psychological care. Psycho-Oncology, 26, 444–451.
L.M. Buffart, et al. Clinical Psychology Review 80 (2020) 101882
14
